Genmab — April 2015
-
Det satser vi på.
-
http://www.proinvestor.com/index.php?p=debat_1&postid=72159 Exiqon analyse
-
Tror nu ikke det er min analyse. Tror mere folk bare er ved at få øjnene op for aktien. Når folk kigger på casen kan de flest nok se potentialet
-
Men selvfølgelig er analysen med til at få folk til at kigge den vej.
-
Det eneste der kan bekymre mig mht. Exiqon er at jeg ikke er særlig bull på $ fremadrettet. Men det kan jo hedges
-
har en stor portion EUR/$ call optioner fordi flere af mine selskaber som genmab, exiqon mv. er lidt følsomme mod $
-
herudover købt CAD/USD fordi jeg mener den canadiske $ er alt for langt nede
-
TF-ADC demonstrated effective killing against tumor cell lines with variable levels of target expression. In xenograft models, TF-ADC was relatively potent in reducing tumor growth compared to EGFR- and HER2- ADCs. We hypothesize that the constant turnover of TF on tumor cells, makes this protein specifically suitable for an ADC approach.http://www.ncbi.nlm.nih.gov/pubmed/25724665
-
J&J fokuserer på farma frem for medico
Medicinaldivisionen går fremad, mens Johnson & Johnson må se koncernens medicodivision tage et tocifret dyk. Det kan få giganten til at skære medicoaktiviteterne ned.
(medwatch.dk)
-
ja vi får abstract release + J&J R&D dag
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind